52 studies found for:    "Genital Diseases, Female" | Japan
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: TAK-385;   Drug: Leuprorelin acetate
2 Active, not recruiting TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: Paclitaxel;   Drug: AMG 386 Placebo;   Drug: Carboplatin
3 Active, not recruiting Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis
Condition: Endometriosis
Interventions: Drug: EE20/DRSP(BAY86-5300);   Drug: Placebo;   Drug: Dienogest
4 Completed The Study Of Fluconazole For Vulvovaginal Candidiasis
Condition: Vulvovaginal Candidiasis
Intervention: Drug: Fluconazole
5 Recruiting Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: temsirolimus;   Drug: docetaxel;   Other: laboratory biomarker analysis
6 Not yet recruiting Bay98-7196, Dose Finding / POC Study
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: Levonorgestrel;   Drug: Anastrozole + Levonorgestrel (BAY 98-7196);   Drug: Lupron / Leuprolide acetate
7 Recruiting Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
Conditions: Anovulation;   Oligo-ovulation;   Hypothalamic-pituitary Dysfunction;   Polycystic Ovarian Syndrome
Interventions: Drug: MSJ-0011;   Drug: urinary hCG
8 Completed Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel
9 Active, not recruiting
Has Results
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Other: hydrocortisone/placebo;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
10 Active, not recruiting TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: AMG 386 Placebo;   Drug: Paclitaxel
11 Recruiting Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
12 Active, not recruiting
Has Results
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: olaparib;   Drug: paclitaxel;   Drug: carboplatin;   Drug: Drug: carboplatin
13 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
14 Recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg
15 Recruiting Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous);   Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
16 Recruiting Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance;   Atypical Endometrial Hyperplasia;   Atypical Glandular Cell of Undetermined Significance;   Cervical Cancer;   Cervical Intraepithelial Neoplasia Grade 2;   Cervical Intraepithelial Neoplasia Grade 3;   Human Papilloma Virus Infection
Intervention: Other: laboratory biomarker analysis
17 Completed Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
18 Completed
Has Results
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo
19 Completed A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: TAK-385;   Drug: Leuprorelin acetate
20 Recruiting Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years